𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: The ESCALE study (SFCE)

✍ Scribed by Jérémie Rudant; Florence Menegaux; Guy Leverger; André Baruchel; Brigitte Nelken; Yves Bertrand; Olivier Hartmann; Hélène Pacquement; Cécile Vérité; Alain Robert; Gérard Michel; Geneviève Margueritte; Virginie Gandemer; Denis Hémon; Jacqueline Clavel


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
98 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The role of a family history of cancer in the etiology of childhood hematopoietic malignancies was investigated using the data from the ESCALE study. ESCALE, a population‐based case–control study, was carried out in France over the period, 2003–2004. A total of 773 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 163 of non‐Hodgkin's lymphoma (NHL) and 1,681 population‐based controls were included. The controls were randomly selected from the French population and were frequency matched with the cases on age and gender. Cancer history in first‐ and second‐degree relatives was reported by the mothers in a structured telephone questionnaire that was the same for the cases and controls. Odds ratios (ORs) were estimated using an unconditional regression model taking into account the stratification variables and potential confounders. A family history of cancer was associated with an increased risk of HL (OR = 1.5 [1.0–2.2]) and NHL (OR = 1.8 [1.3–2.5]), but not AL (OR = 1.0 [0.9–1.2]). The ORs were higher when at least 2 relatives had a history of cancer or when 1 case occurred before age 46 years. Only HL was significantly associated with a family history of hematopoietic malignancies (OR = 2.0 [1.0–3.8]), mainly because of a significant association with a history of HL (OR = 5.4 [1.3–22]). In conclusion, the study findings support the hypothesis of familial susceptibility to childhood lymphoma, but do not suggest familial susceptibility to childhood AL. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Longitudinal growth in children with non
✍ Márky, Ildikó ;Samuelsson, Bengt-Olof ;Mellander, Lotta ;Karlberg, Johan 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

Longitudinal growth was studied in children treated for non-Hodgkin's lymphoma (NHL). The aim of the study was to compare these children's growth velocity with findings in a previous study we performed on age-matched children with acute lymphoblastic leukemia (ALL) who received cranial irradiation.

Severe myelotoxicity of oral etoposide i
✍ Sharon Shaklai; Osnat Bairey; Dorit Blickstein; Miron Prokocimer; Herzlia Hadar; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB 👁 2 views

## BACKGROUND. Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. Due to the small number of patients reported, information regarding side effects is limited, and therefore warrants further evaluation. ## METHODS. Twenty eligible

The EcoRI rflp of c-MOS in patients with
✍ G. Chenevix-Trench; M. Southall; C. Kidson 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 407 KB

## NON-GERIATRIC CONTROLS We have used Southern blot analysis to type individuals for the presence or absence of a rare EcoRl RFLP at the c-mos proto-oncogene locus. This polymorphism has previously been reported to be associated with cancer. Ninety-eight patients with non-Hodgkin's lymphoma (NHL)

Phase II trial of ifosfamide and mesna i
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and